ARCHIVES

Phase II Study Of Pfizer Drug Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

NCI Extends PRI’s Fredrick Contract Six Months

September 23, 1994

DeVita Defends CHP Awards, Says Program Has High Priority

September 5, 1980

CTRC, UCLA Receive Gifts; NCCF Distributes Gold Pins.

March 24, 2000

Letter: No Intent To Link Flags With NSABP Inquiry, ORI’s Bivens Writes

March 10, 1995

Letters: NCI Mammography Statement Recognizes Patient Autonomy

February 25, 1994

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003